GlassScriptPhysician profile
Brandon Lennep
NPI 1073953147
$19,679.64
in general payments reported to CMS, 2019-2025
27 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,851 · 2020: $563 · 2021: $697 · 2022: $7,339 · 2023: $4,445 · 2024: $379 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,700 · Food and Beverage: $1,330 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,700.00 |
| Food and Beverage | $1,330.13 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,861.06 | 2019-2025 | |
| Medtronic Vascular, INC. | $2,881.34 | 2019 | |
| Abbott Laboratories | $1,999.91 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $681.75 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $410.20 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $404.74 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $316.89 | 2020-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $257.75 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $234.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $214.52 | 2020-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $187.70 | 2019-2024 | Camzyos |
| United Therapeutics Corporation | $156.45 | 2019-2024 | Tyvaso, Remodulin, Orenitram |
| Lantheus Medical Imaging, INC. | $142.74 | 2019 | |
| Astellas Pharma US INC | $128.16 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $108.74 | 2019-2023 | Zio Xt Patch |
| Impulse Dynamics (USA) INC. | $96.89 | 2021-2023 | Optimizer |
| Braemar Manufacturing, LLC | $72.78 | 2019 | |
| Bridgebio Pharma, INC. | $66.69 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $62.90 | 2019-2022 | |
| Philips North America LLC | $54.91 | 2024-2025 | Lm Undivided, Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $18.68 | 2025 | Amvuttra |
| Akcea Therapeutics, INC. | $15.22 | 2020 | |
| Glaxosmithkline, LLC. | $15.16 | 2025 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $13.47 | 2024 | |
| Vifor Pharma, INC. | $12.89 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.06 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Lennep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.